Journal of the American Academy of Child & Adolescent Psychiatry
ArticlesA Prospective, Open-Label Trial of Olanzapine in Adolescents With Schizophrenia
Section snippets
METHOD
This study was an 8-week, open-label, prospective outpatient trial of olanzapine in adolescents with a schizophrenia spectrum disorder in which the subjects were seen biweekly. Subjects were recruited from within the auspices of the clinical and research infrastructures within a midwestern academic division of child and adolescent psychiatry. The Institutional Review Board for Human Investigation at University Hospitals of Cleveland approved the procedures that were performed under the auspices
RESULTS
Seventeen subjects signed informed consent and were enrolled in this trial. One of these subjects withdrew consent before the baseline visit. Therefore, 16 subjects were actually administered study medication. All data reported herein are based on these 16 teenagers.
DISCUSSION
Overall, olanzapine was well tolerated and was associated with amelioration of both positive and negative psychotic symptoms in this outpatient population. However, patients did have residual symptoms at study's end. Strengths of this study include its diagnostic homogeneous patient population, its emphasis on a community-based cohort, its prospective design, and its 8-week duration.
Besides being complementary to the available information regarding the use of olanzapine in
REFERENCES (33)
- et al.
Risperidone in adolescents with schizophrenia
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Antipsychotics in children and adolescents
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data
J Am Acad Child Adolesc Psychiatry
(1997) The diagnosis and treatment of children and adolescents with schizophrenia: “my mind is playing tricks on me.”
Child Adolesc Psychiatr Clin N Am
(2000)- et al.
Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Child and adolescent schizophrenia
Psychiatr Clin North Am
(1998) Placebo-controlled trials in schizophrenia: Are they ethical? Are they necessary?
Schizophr Res
(1999)Diagnostic and Statistical Manual of Mental Disorders
(1994)- et al.
Do we need placebos to evaluate new drugs in children with schizophrenia?
Psychopharmacology
(2002) A rating scale for drug-induced akathisia
Br J Psychiatry
(1989)
Age at onset in subtypes of schizophrenic disorders
Schizophr Bull
Adolescent onset psychosis: a clinical and outcome study
J Child Psychol Psychiatry
Paediatric uses of atypical antipsychotics
Expert Opin Pharmacother
Psychotic disorders diagnosed in adolescence: outcome at age 30 years
J Child Psychol Psychiatry
The influence of age and sex on the onset and early course of schizophrenia
Br J Psychiatry
Analysis of variance frameworks in clinical child and adolescent psychology: issues and recommendations
J Clin Child Adolesc Psychol
Cited by (56)
Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: A systematic review and meta-analysis
2023, Journal of Psychiatric ResearchEmpirical Evidence for Psychopharmacologic Treatment in Early-Onset Psychosis and Schizophrenia
2012, Child and Adolescent Psychiatric Clinics of North AmericaCharacteristics and anxiety symptom presentation associated with autism spectrum traits in youth with anxiety disorders
2012, Journal of Anxiety DisordersCitation Excerpt :Scores range from 0 to 100, with lower scores reflecting greater impairment. The CGAS has adequate inter-rater reliability (Dyrborg et al., 2000; Shaffer et al., 1983), retest reliability (Bird, Canino, Rubio-Stipec, & Ribera, 1987), sensitivity to change over time (e.g., Findling et al., 2003), and discriminant validity (Steinhausen & Metzke, 2001). Inter-rater reliability for the CGAS among diagnosticians in the clinic was found to be acceptable (intraclass correlation = .73).
Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS): Rationale, design, and methods
2007, Journal of the American Academy of Child and Adolescent Psychiatry
From the Departments of Psychiatry and Pediatrics, Case Western Reserve University School of Medicine and University Hospitals of Cleveland and the Department of Psychiatry, University of Minnesota, Minneapolis.
This study was primarily sponsored by Eli Lilly and was supported in part by a Clinical Research Center Grant from the Stanley Medical Research Institute.